| Literature DB >> 27956623 |
Fotini Vogiatzi1, Dominique T Brandt2, Jean Schneikert1, Jeannette Fuchs1, Katharina Grikscheit2, Michael Wanzel1, Evangelos Pavlakis1, Joël P Charles1, Oleg Timofeev1, Andrea Nist3, Marco Mernberger1,3, Eva J Kantelhardt4, Udo Siebolts5, Frank Bartel5, Ralf Jacob6, Ariane Rath7, Roland Moll7, Robert Grosse2, Thorsten Stiewe8,3,9.
Abstract
Mutations in the p53 tumor suppressor gene are the most frequent genetic alteration in cancer and are often associated with progression from benign to invasive stages with metastatic potential. Mutations inactivate tumor suppression by p53, and some endow the protein with novel gain of function (GOF) properties that actively promote tumor progression and metastasis. By comparative gene expression profiling of p53-mutated and p53-depleted cancer cells, we identified ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) as a mutant p53 target gene, which functions as a uridine 5'-diphosphatase (UDPase) in the endoplasmic reticulum (ER) to promote the folding of N-glycosylated membrane proteins. A comprehensive pan-cancer analysis revealed a highly significant correlation between p53 GOF mutations and ENTPD5 expression. Mechanistically, mutp53 is recruited by Sp1 to the ENTPD5 core promoter to induce its expression. We show ENTPD5 to be a mediator of mutant p53 GOF activity in clonogenic growth, architectural tissue remodeling, migration, invasion, and lung colonization in an experimental metastasis mouse model. Our study reveals folding of N-glycosylated membrane proteins in the ER as a mechanism underlying the metastatic progression of tumors with mutp53 that could provide new possibilities for cancer treatment.Entities:
Keywords: ENTPD5; N-glycosylation; metastasis; p53; tumor suppressor
Mesh:
Substances:
Year: 2016 PMID: 27956623 PMCID: PMC5206569 DOI: 10.1073/pnas.1612711114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205